Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol sedation for repeated interstitial brachytherapy in cervical cancer
ChiCTR2500108294Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in Cervical Cancer (CC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Intraoperative adverse effects. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500108294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108294.